{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '7.5', 'Analysis of Safety', '89', '7.5.1', 'Adverse Events', '89', '7.5.2', 'Laboratory Assessments', '90', '7.5.3', 'Vital Signs', '90', '7.5.4', 'Routine 12-lead Electrocardiograms', '90', '7.5.5', 'ECOG Performance Status', '90', '7.5.6', 'Exposure-Response Relationship Analysis', '90', '7.6', 'Analysis of Pharmacokinetics', '90', '7.7', 'Major Protocol Deviations and Other Analyses', '90', '7.8', 'Interim Analysis (and Early Discontinuation of the Clinical Study)', '91', '7.9', 'Handling of Missing Data, Outliers, Visit Windows, and Other Information', '91', '8', 'OPERATIONAL AND ADMINISTRATIVE CONSIDERATIONS', '91', '8.1', 'Procedure for Clinical Study Quality Control', '91', '8.1.1', 'Data Collection', '91', '8.1.2', 'Specification of Source Documents', '92', '8.1.3', 'Clinical Study Monitoring', '93', '8.1.4', 'Direct Access to Source Data/Documents', '93', '8.1.5', 'Data Management', '93', '8.1.6', 'Major Protocol Deviations', '93', '8.1.7', 'End of Trial in All Participating Countries', '94', '8.2', 'Ethics and Protection of Subject Confidentiality', '94', '8.2.1', 'Institutional Review Board/Independent Ethics Committee/Competent', 'Authorities', '94', '8.2.2', 'Ethical Conduct of the Study', '95', '8.2.3', 'Informed Consent of Subjects', '95', '8.2.3.1', 'Subject Information and Consent', '95', '8.2.3.2', \"Supply of New and Important Information Influencing the Subject's\", 'Consent and Revision of the Written Information', '95', '8.2.4', 'Subject Confidentiality and Privacy', '96', '8.3', 'Administrative Matters', '96', '8.3.1', 'Arrangement for Use of Information and Publication of the Clinical Study', '96', '8.3.2', 'Documents and Records Related to the Clinical Study', '97', '8.3.3', 'Protocol Amendment and/or Revision', '98', '8.3.4', 'Insurance of Subjects and Others', '99', '8.3.5', 'Signatory Investigator for Clinical Study Report', '99', '14 Sep 2020', 'Astellas', 'Page 6 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '9', 'QUALITY ASSURANCE', '100', '10', 'STUDY ORGANIZATION', '100', '10.1', 'Independent Data-Monitoring Committee', '100', '11', 'REFERENCES', '101', '12', 'APPENDICES', '103', '12.1', 'List of Cautionary Concomitant Medications', '103', '12.2', 'Liver Safety Monitoring and Assessment', '104', '12.3', 'Common Serious Adverse Events', '107', '12.4', 'Retrospective PGx Sub-Study', '108', '12.5', 'EORTC-QLQ-30', '110', '12.6', 'EQ-5D-5L', '112', '12.7', 'Health Resource Utilization', '114', '12.8', 'RECIST V1.1', '116', '12.9', 'ECOG Performance Status', '118', '12.10', 'Crossover Extension', '119', '12.10.1', 'Rationale', '119', '12.10.2', 'Inclusion Criteria', '119', '12.10.3', 'Exclusion Criteria', '119', '12.10.4', 'Schedule and Assessments', '120', '12.10.5', 'Duration of Treatment and Discontinuation Criteria', '126', '12.10.6', 'Statistical Methods', '127', '13', 'ATTACHMENT 1: SUBSTANTIAL AMENDMENT 3', '128', '14', \"COORDINATING INVESTIGATOR'S SIGNATURE\", '142', '15', \"SPONSOR'S SIGNATURES\", '143', '14 Sep 2020', 'Astellas', 'Page 7 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}